Qube Research & Technologies LTD Immuno Gen, Inc. Transaction History

Qube Research & Technologies LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$12.46 - $29.95 $3.29 Million - $7.9 Million	263,880 New	263,880 $7.82 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $156,033 - $209,178	42,516 New	42,516 $163,000
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $1.45 Million - $2.09 Million	323,133 Added 2640.62%	335,370 $1.6 Million
Q2 2022 Aug 15, 2022	BUY	$3.15 - $5.76 $38,546 - $70,485	12,237 New	12,237 $55,000
Q4 2021 Feb 01, 2022	SELL	$4.75 - $7.5 $49,761 - $78,570	-10,476 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$5.02 - $6.59 $214,615 - $281,735	-42,752 Reduced 80.32%	10,476 $59,000
Q2 2021 Aug 13, 2021	SELL	$5.79 - $8.6 $123,674 - $183,696	-21,360 Reduced 28.64%	53,228 $351,000
Q1 2021 May 14, 2021	BUY	$6.5 - $10.53 $336,550 - $545,211	51,777 Added 226.98%	74,588 $604,000
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $84,400 - $174,732	22,811 New	22,811 $147,000
Q3 2020 Nov 12, 2020	SELL	$3.45 - $4.89 $313,201 - $443,928	-90,783 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$3.32 - $5.34 $301,399 - $484,781	90,783 New	90,783 $418,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.